# Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc is an other based in Bridgewater, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Bridgewater, United States
- **Region:** North America
- **Address:** Bridgewater, NJ, United States
- **Assets under management:** Undisclosed
- **Website:** osmotica.com

## Regulatory record

- **Reports private funds:** No

## About

Osmotica Pharmaceuticals plc, headquartered in Bridgewater, New Jersey, was established as a specialty pharmaceutical entity focused on the development and commercialization of both branded and generic products. The company leverages osmotic drug delivery technology to create differentiated therapies. Its wealth origin is not publicly attributed to a specific family or individual, as Osmotica operated as a publicly traded entity on the Nasdaq before being acquired. The firm's strategy revolves around a mix of proprietary and generic product development, targeting areas such as central nervous system disorders and urological therapies. Osmotica's product pipeline includes the branded treatment Osmolex ER for Parkinson's disease, along with generic versions of established drugs. The geographic footprint centers on the United States market, with manufacturing and development operations also in Latin America (Argentina). While specific fund structures are not applicable, the company historically financed operations through public equity markets and strategic partnerships. As a public company, Osmotica employed a team of scientists and commercial personnel, with operations split between its US headquarters and manufacturing facilities in Buenos Aires. In 2021, the company was acquired by private equity firm Altaris Capital Partners for approximately $230 million, taking it private (per SEC filings, 2021). Adjacent vehicles or philanthropic structures are not publicly disclosed. A genuine structural differentiator is Osmotica's specialization in osmotic drug delivery, a complex formulation technology that creates barriers to entry for competitors. This focus on niche, hard-to-replicate pharmaceutical products distinguishes its approach from broader generic manufacturers and aligns with its acquisition by a healthcare-focused private equity firm.

## Sectors

- Pharmaceuticals

## Questions

### Who owns Osmotica Pharmaceuticals after its public delisting?

Osmotica Pharmaceuticals was acquired by Altaris Capital Partners, a healthcare-focused private equity firm, in 2021 for approximately $230 million. Following the acquisition, Osmotica became a privately held company (per SEC filings, 2021).

### What drug delivery technology does Osmotica specialize in?

Osmotica specializes in osmotic drug delivery technology, which uses osmotic pressure to control the release rate of active ingredients. This technology is used in products like Osmolex ER for Parkinson's disease. The expertise in this complex formulation creates a competitive advantage.

### What therapeutic areas does Osmotica focus on?

The company focuses on central nervous system disorders and urological conditions. Its branded product Osmolex ER treats Parkinson's disease. Osmotica also develops generic versions of drugs targeting these therapeutic areas.

### What investment stages does Osmotica operate within?

As a specialty pharmaceutical company, Osmotica operates in the development and commercialization stages, bringing products from clinical trials to market. It historically funded R&D through public equity and partnerships, now under private equity ownership.

## Related profiles

- [Argan](https://altss.com/profile/argan)
- [Tohokushinsha Film Corporation](https://altss.com/profile/tohokushinsha-film-corporation)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/osmotica-pharmaceuticals-plc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology